NCT04028518 is a Phase 2 clinical trial of r-PA in Acute Ischemic Stroke, sponsored by Angde Biotech Pharmaceutical Co., Ltd..

Who is sponsoring NCT04028518?

NCT04028518 is sponsored by Angde Biotech Pharmaceutical Co., Ltd..

What drugs are being tested in NCT04028518?

Interventions in NCT04028518: r-PA, r-PA, Alteplase for Injection.

What condition does NCT04028518 study?

NCT04028518 studies Acute Ischemic Stroke.

Is NCT04028518 still recruiting?

NCT04028518 is currently status unknown. Last updated 22 July 2019.

Last reviewed 2019-07-22 · How we verify

NCT04028518

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.

Status unknown Phase 2 Last updated 22 July 2019

What this trial tests

Phase 2 trial testing r-PA in Acute Ischemic Stroke in 180 participants. Status unknown.

Timeline

20 July 2019

Primary endpoint
31 October 2020

31 March 2021

Quick facts

Lead sponsor	Angde Biotech Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	20 July 2019
Primary completion	31 October 2020
Estimated completion	31 March 2021
Sites	1 location across China

Drugs / interventions tested

r-PA — full drug profile →
r-PA — full drug profile →
Alteplase for Injection — full drug profile →

Conditions studied

Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →

Sponsor

Angde Biotech Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this trial is to compare the efficacy of different doses of investigator product and comparator product in patients with acute ischemic stroke in 4.5 Hours after stroke onset, and provide a basis of drug administration for phase Ⅲ clinical trial. The secondary purpose of this trial is to compare the safety of different dose of investigational product and comparator product in patients with acute ischemic stroke in 4.5 hours afterstroke onset .

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial.
Li S, Wang X, Jin A, Liu G, et al · · 2024 · cited 19× · PMID 38152962 · DOI 10.1161/strokeaha.123.045193
Thrombolytic therapy for patients with acute ischemic stroke: systematic review and network meta-analysis of randomized trials.
Sun LC, Li WS, Chen W, Ren Z, et al · · 2024 · cited 6× · PMID 39839875 · DOI 10.3389/fneur.2024.1490476

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke

Currently open trials in the same condition.

NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting

Other Angde Biotech Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT05629598 — A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia . · Phase 2 · unknown
NCT05295173 — A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE） · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04028518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Angde Biotech Pharmaceutical Co., Ltd.
Last refreshed: 22 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04028518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing